Belharra Therapeutics Partners with Sanofi to Discover New Small Molecules Addressing Immunological Diseases
Shots:
- Belharra & Sanofi have partnered to discover new small molecules for immunological diseases using Belharra’s non-covalent chemo proteomics platform to screen & validate targets for Sanofi's undisclosed immunology targets
- Under the agreement, Belharra will obtain ~$40M upfront & near-term milestones, making it a total deal value of ~$700M to be paid further as research, development & commercial milestones plus tiered net-sales-based royalties
- Belharra’s platform consists of a collection of non-covalent drug-like molecules that identify the proteins binding with the molecules & binding sites on target proteins which are illuminated, generating insights to discover new drugs for protein targets & new drug targets
Ref: Belharra | Image: Belharra
Related News:- Belharra and Genentech Enter into a Research Collaboration to Discover and Develop Small Molecules for Multiple Therapeutic Areas
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
